Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

Study Objective. To evaluate and compare the relationship between dosage an d coagulation parameters, as well as safety profiles, of ascending bolus an d infusion dosages of argatroban versus heparin in three phase I studies. Design. Two randomized, double-blind studies compared argatroban and hepari n, and one open-label, dose-escalation study further evaluated argatroban. Setting. University teaching hospital clinical research unit. Patients. Healthy men (aged 22-62 yrs). Intervention. In the first study 36 subjects received an argatroban 30-, 60 -, 120-, or 240-mu g/kg bolus, or a heparin 30-, 60-, 120-, or 240-U/kg bol us for three subjects, then amended to 15, 30, 60, or 120 U/kg. In the seco nd study, 37 subjects received argatroban 1.25, 2.5, 5, or 10 mu g/kg/minut e with or without a 250-mu g/kg bolus, or heparin 0.15, 0.20, 0.25, or 0.30 U/kg/minute with or without a 125-U/kg bolus. In the third study (open-lab el), nine subjects received an argatroban 250-mu g/kg bolus plus an infusio n of 15, 20, 30, and 40 mu g/kg/minute. Measurements and Main Results. When administered as a bolus dose in the fir st study, argatroban and heparin both produced dose-related increases in ac tivated clotting time (ACT) and activated partial thromboplastin time (aPTT ) within 10 minutes of administration. Dissipation of anticoagulant effect was approximately 4-fold faster for argatroban than for heparin. When admin istered by infusion with or without a bolus in the second study, argatroban , but not heparin, produced predictable dose-related increases in ACT and a PTT that were generally consistent across both effect measures and modes of administration. Effect steady state was attained by five or more subjects per dosing group receiving argatroban (5-9) but typically two or fewer subj ects per group receiving heparin (0-7). Furthermore, upon cessation of infu sion, anticoagulant effects dissipated faster for argatroban (effect half-l ife 18-41 min) than for heparin (effect half-life 23-134 min). When argatro ban was infused without a bolus, peak and effect steady-state values for AC T and aPTT generally were attained within 1-3 hours. Data from the second a nd third studies show that for argatroban dosages up to 40 mu g/kg/minute, plasma drug concentrations attained at 4 hours of infusion increased linear ly with dose, and weight-adjusted plasma clearance was dose independent. In all studies, argatroban and heparin were well tolerated. Conclusion. Anticoagulation was more predictable with argatroban than with heparin as measured by ACT and aPTT, with comparable safety profiles.